Full-Time

Senior Research Scientist

Modelling & Simulations

Confirmed live in the last 24 hours

AbCellera Biologics

AbCellera Biologics

501-1,000 employees

Biotechnology firm specializing in antibody therapies

Compensation Overview

CA$114k - CA$142.6k/yr

+ Equity + Annual Bonus

Senior

Vancouver, BC, Canada

Category
Lab & Research
Interdisciplinary Research
Life Sciences
Required Skills
Python
R
Julia
MATLAB
Data Analysis
Requirements
  • PhD in Mathematics, Pharmaceutical Sciences, Computational Biology, or a related field
  • Minimum of 5-8 years of relevant experience, including experience in an industry environment
  • Hands-on experience in Quantitative Pharmacology and/or Pharmacometric approaches with a focus on QSP and PK/PD modeling in pre-clinical or early clinical development
  • Excellent understanding of theory, principles, and statistical aspects of mathematical modeling and simulation, including using numerical methods and parameter estimation/optimization
  • Hands-on experience using mathematical modeling software (e.g., Matlab, Simbiology, NONMEM, Julia, Monolix)
  • Experience with data analysis and visualization software (e.g., R, Python)
  • Good understanding of pharmacokinetic and pharmacodynamic principles for antibody and small molecule therapeutics
  • Ability to learn new areas of biological sciences and integrate the knowledge and data to develop QSP models
  • Experience supporting and working with cross-functional teams in a dynamic environment
  • Demonstrated ability to find creative and functional solutions to complicated problems
  • Ability to express complex ideas in understandable ways, and to communicate effectively with people from different fields
  • Excellent documentation skills with impeccable attention to detail
Responsibilities
  • Collaborating with scientists across Discovery and Development to develop and execute modeling strategies that contribute to project team discussions and guide therapeutic and dose selection decisions
  • Developing and implementing Quantitative Systems Pharmacology (QSP) and PK/PD modeling strategies to predict the behavior of therapeutics in disease-relevant systems and provide mechanistic understanding of the PK and PD profile
  • Partnering with the Pharmacology and Pharmacokinetics teams to support study design and analysis of data from in vivo studies
  • Collaborating with Clinical Pharmacology and Biostatistics experts to integrate modeling and simulation strategies to answer questions around clinical trial design and dose selection
  • Performing sensitivity analysis and hypothesis testing in order to identify key design parameters of interest for antibody molecules
  • Presenting findings and results in a concise manner to a diverse audience
  • Acting as a subject matter expert in projects where modeling and simulations input is required

AbCellera specializes in discovering and developing therapeutic antibodies for various diseases. The company uses a proprietary technology platform that combines different scientific methods to identify and create antibodies efficiently. Clients, including pharmaceutical companies and research institutions, partner with AbCellera to enhance their drug development processes. Unlike many competitors, AbCellera focuses on challenging targets that traditional methods struggle to address. The company's goal is to accelerate the development of new antibody therapies through collaboration and its own internal programs, generating revenue from partnerships, discovery services, and licensing agreements.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Vancouver, Canada

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • Expanded collaboration with AbbVie enhances AbCellera's oncology capabilities and market reach.
  • Partnerships with Viking and ArrowMark could lead to innovative antibody drug programs.
  • Collaboration with Biogen positions AbCellera as a leader in neurological drug development.

What critics are saying

  • High competition from AI-driven biotech firms may threaten AbCellera's market position.
  • Complexity of blood-brain barrier research with Biogen poses significant R&D risks.
  • Launching new biotech companies may dilute AbCellera's focus and resources.

What makes AbCellera Biologics unique

  • AbCellera excels in rapid antibody discovery with its integrated technology platform.
  • The company partners with leading firms like Eli Lilly and Biogen for diverse therapeutic areas.
  • AbCellera's focus on challenging targets sets it apart in the competitive biotech market.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

Paid Sick Leave

Flexible Work Hours

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
Stock Titan
Jan 13th, 2025
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera (ABCL) has expanded its collaboration with AbbVie (ABBV) to develop novel T-cell engagers (TCE) in oncology, building upon their partnership from December 2022.

North Carolina Biotechnology Center
Sep 30th, 2024
Dualogics Sells Antibody Platform to Canadian Company | North Carolina Biotechnology Center

Durham-based Dualogics has sold its core technology for producing therapeutic antibodies to a Canadian biotechnology company.

Stock Titan
Jul 31st, 2024
AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

AbCellera (Nasdaq: ABCL) has expanded its collaboration with Eli Lilly to develop antibody medicines for immunology, cardiovascular disease, and neuroscience programs.

Securities.io
Jun 13th, 2024
Top 10 Biotech Big Data Companies

More Data For Better MedicineThe more we learn about biology, the more we realize all we do not know. It started with the genomic revolution and the first human genome sequenced in the early 2000s.Genomics has now been joined by other datasets like transcriptomics, proteomics, metabolomics, microbiome, etc. forming a new “multiomics” science. We discussed in further detail this evolution in “ Multiomics Are The Next Step In Biotechnology ”.These new tools have created a flood of data bringing detailed information about the inner activities of cells sometimes down to the atomic level. A key driver of this data growth has been the collapse of price of sequencing gene and other biological materials like proteins.This has created enthusiasm about “Big Data” potential in biotech, mimicking the concept of big data from other, more IT-driven fields.Already in 2018, the magazine Barron’s was asking “ Will Big Data Lead to Big Biotech Returns? ” and the industry started to ask “ Implementing Large-Scale Data Processing and Analysis for Bioprocessing ”Quite a few companies are well-positioned to benefit from the drive to create and analyze at-scale biological data.AI Merging With Big Data?A new development in the last few years has been the emergence of AI. While AI made its way into public consciousness mostly in 2023, with LLMs (Large Language Models) like ChatGPT, the biotech industry started to embrace AI many years before that.And it makes sense because data and AI have a somewhat symbiotic relationship:Training AI models requires a lot of data with high quality and annotations.AIs can help sort out massive datasets without direct human intervention and connect the dots where manual analysis would not be possible.The result is that today, a lot of the previously big data-focused companies in the biotech industry are also turning into AI companies.Contrary to some AI applications still looking for a business model (like image generation), drug discovery and medical research have a pretty straightforward path from AI model to monetization.Top 10 Big Data Biotech StocksIllumina is the leading genomics company, by far the largest and most established in the industry, with $1.2B in revenues, which grew 11% CAGR in the last 5 years.This also makes it the prime provider of genomic data to the entirety of the biotech industry.Like most genome sequencing companies, Illumina makes money when selling sequencers but mostly when selling the consumables used by the sequencers

Seeking Alpha
May 1st, 2024
AbCellera partners with PE firms to develop antibody drugs, company creation

AbCellera (NASDAQ:ABCL) has inked an agreement with Viking Global Investors and ArrowMark Partners to develop new antibody drug programs, with an initial focus on immunology.